12:00 AM
 | 
Apr 04, 2011
 |  BC Week In Review  |  Company News  |  Deals

Ariad, MolecularMD deal

Ariad and MolecularMD will develop and commercialize a companion diagnostic for Ariad's cancer candidate ponatinib. The BCR-ABL tyrosine kinase inhibitor is in Phase II testing in patients with resistant or intolerant...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >